Elizabeth Holmes’ jury trial started last week. Holmes is the black turtleneck clad former CEO of Theranos who affected a deep voice and belief that her company had developed the iPhone of blood testing equipment. The device was supposed to be a one-stop shop for blood testing with a single prick. For those of us who have needle phobia (your authors included), this would be a game changer.

The problem was it didn’t work. Investors were mostly fooled and poured money into the company with lofty valuations unsupported by any real financial data or actual technology. So was the board. In 2014, Forbes said Holmes was the youngest billionaire ever, mostly based on Theranos stock, which would later turn out to be worthless. A Wall Street Journal reporter named John Carreyrou ran a series of articles that exposed that the company was smoke and mirrors. If the trial is anything like Carreyrou’s book, “Bad Blood,” it should be fascinating.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]